News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phase Bioscience, Inc. Announces Positive Clinical Results with its Once Weekly GLP-1 Analogue, Glymera™ for the Treatment of Hyperglycemia in Patients with Type 2 Diabetes


11/15/2011 7:25:19 AM

MALVERN, Pa.--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc., announced today positive results from its Phase I/IIa single and multiple ascending dose clinical study with Glymera™, a recombinant glucagon-like peptide-1 (GLP-1) analogue for the treatment of hyperglycemia in patients with type 2 diabetes. In a dose dependent manner, Glymera™ demonstrated highly statistically significant reductions in fasting glucose glycemic load following meal tolerance testing, and average daily glucose measured through continuous glucose monitoring following 4 weeks of dosing.

Read at BioSpace.com

comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES